In this episode of the Spotlight Media Podcast, Dennis Walker speaks with Edward Crowe – music industry executive, photographer, and psychonaut – about how his relationship with psilocybin mushrooms helps him navigate his personal and professional life.
Similar Posts
5 Fascinating Insights From a Top Psychedelics Researcher
Dr. Matthew Johnson, one of the most published psychedelics researchers in the world, shares two decades worth of wisdom.
Psilocybin Is Effective in Reducing Weight Gain, New Study Shows
NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects.
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Mixing Psychedelics & Antidepressants: Is it Safe? | NEW Psilocybin Study
As using psychedelics as medicines for mental health conditions has become more popular, it has been an open question of whether substances such as psilocybin (magic mushrooms) can safely be combined with anti-depressants such as SSRIs.
Now, Compass Pathways (CMPS) has released a small study, which showed that it is in fact safe to combine the two drugs. This is the second such small study to come to this conclusion. Earlier this year, MindMed, (MNMD / MMED) had released data on a similar study, with similar results
However, it is important to note that these are two very small studies, and that nothing has been definitively proven yet.
Many argue that psychedelics like psilocybin should be a replacement for depression medications such as SSRIs, not another layer of medicine. While I am sympathetic to this view, we must ultimately follow the science.
Compass Pathways will use the results of this trial to inform the design of their upcoming phase 3 trial testing whether psilocybin can treat treatment resistant depression.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
#psychedelics #antidepressants #psilocybin
Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized Communities
“It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” says Cybin Chief Clinical Officer Dr. Alex Belser.